Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia
- 1 January 1983
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 7 (4) , 539-545
- https://doi.org/10.1016/0145-2126(83)90048-6
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?British Journal of Haematology, 1982
- Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemiaBlood, 1981
- Dose-dependent effects of a tumor promotor on blast cell progenitors in human myeloblastic leukemiaBlood, 1981
- DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1979
- Advances in the Treatment of Acute Myelogenous LeukemiaNew England Journal of Medicine, 1979
- Cell flux studies during chemotherapy with multiple doses of arabinosyl cytosine in chronic myeloid leukemiaLeukemia Research, 1977
- The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA)Cancer, 1977
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Arabinosyl Cytosine in Chronic Myeloid Leukaemia: Evidence for High Cytokinetic Sensitivity of MyeloblastsScandinavian Journal of Haematology, 1976